Literature DB >> 1055404

Lymphocyte cytotoxicity to autologous liver cells in chronic active hepatitis.

K R Wands, K J Isselbacher.   

Abstract

Lymphocyte function in vitro was evaluated in patients with chronic active hepatitis and compared to normal controls. Circulating lymphocytes of patients were spontaneously cytotoxic to 51Cr-labeled human Chang liver cells and to suspensions of autologous liver cells obtained at the time of liver biopsy when tested at a lymphocyte target cell ratio of 200:1. Prednisone treatment of patients with chronic active hepatitis inhibited both spontaneous and concanavalin A-stimulated lymphocyte cytotoxicity to human Chang liver cells. Similarly, chronic prednisone administration substantially reduced lymphocyte cytotoxicity towards the patients' own liver cells in vitro, which correlated with a clinical, biochemical, and histological response to such therapy. Thus, patients with chronic hepatitis have circulating lymphocytes that are capable of causing destruction of their own liver cells in vitro. The beneficial effect of prednisone therapy in such patients may be related to this inhibition of lymphocyte cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1055404      PMCID: PMC432520          DOI: 10.1073/pnas.72.4.1301

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  Human lymphocyte subpopulations. Effect of corticosteroids.

Authors:  D T Yu; P J Clements; H E Paulus; J B Peter; J Levy; E V Barnett
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis.

Authors:  A D Thomson; M A Cochrane; I G McFarlane; A L Eddleston; R Williams
Journal:  Nature       Date:  1974-12-20       Impact factor: 49.962

3.  Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

Authors:  R D Soloway; W H Summerskill; A H Baggenstoss; M G Geall; G L Gitnićk; I R Elveback; L J Schoenfield
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

4.  Hemagglutination assay for antigen and antibody associated with viral hepatitis.

Authors:  G N Vyas; N R Shulman
Journal:  Science       Date:  1970-10-16       Impact factor: 47.728

5.  The effect of in vivo hydrocortisone on subpopulations of human lymphocytes.

Authors:  A S Fauci; D C Dale
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

6.  Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction.

Authors:  I R Cohen; L Stavy; M Feldman
Journal:  J Exp Med       Date:  1970-12-01       Impact factor: 14.307

7.  Immunologic studies in patients with chronic active hepatitis and primary biliary cirrhosis. I. Cytotoxic activity and binding of sera to human liver cells grown in tissue culture.

Authors:  F Paronetto; M Gerber; S J Vernace
Journal:  Proc Soc Exp Biol Med       Date:  1973-07
  7 in total
  30 in total

1.  Flow cytometric and functional analysis of mononuclear cells infiltrating the liver in experimental autoimmune hepatitis.

Authors:  H Kohda; C Sekiya; M Kanai; Y Yoshida; T Uede; K Kikuchi; M Namiki
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  T and B lymphocytes in patients with chronic active hepatitis (CAH).

Authors:  M Colombo; S J Vernace; F Paronetto
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

3.  Alteration in suppressor cell activity in chronic active hepatitis.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

4.  In vitro morphological studies on antibody-dependent nonimmune lymphocyte-mediated cytotoxicity in chronic active liver disease.

Authors:  H Kawanishi
Journal:  Am J Dig Dis       Date:  1978-02

5.  Disordered immunoregulatory functions in patients with chronic active hepatitis.

Authors:  A Nonomura; M Tanino; H Kurumaya; G Ohta; Y Kato; K Kobayashi
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Lymphocyte-mediated cytotoxicity in isoniazid-associated hepatitis.

Authors:  R J Warrington; S L Olivier
Journal:  Clin Exp Immunol       Date:  1979-12       Impact factor: 4.330

7.  Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease.

Authors:  J Sanchez-Tapias; H C Thomas; S Sherlock
Journal:  Gut       Date:  1977-06       Impact factor: 23.059

8.  Lymphocyte cytotoxicity in chronic active hepatitis: effect of therapy and correlations with clinical and histological changes.

Authors:  A M Cochrane; A Moussouros; A Smith; B Portmann; A L Eddleston; R Williams
Journal:  Gut       Date:  1978-04       Impact factor: 23.059

9.  Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis.

Authors:  H F Eggink; H J Houthoff; S Huitema; C H Gips; S Poppema
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

10.  Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg positive chronic liver disease.

Authors:  G Mieli-Vergani; D Vergani; B Portmann; Y White; I Murray-Lyon; J H Marigold; I Woolf; A L Eddleston; R Williams
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.